No diagnostic value is attributed to gastric emptying tests (statements 41 and 42)
Regarding the regulatory environment: while the tirzepatide and semaglutide shortages have resolved, Empower maintains that 503A pharmacies may still compound these drugs if they meet clinical difference criteria under Section 503A of the Federal Food, Drug & Cosmetic Act
In this way, it serves as a proofofconcept that even a peptide or protein drug known to have poor bioavailability can still be delivered orally, and without any modification, if we compensate by delivering a sufficiently high dose
This suggests that their taste preferences may be changing
**Research Applications and Mechanism of Action** Laboratory research has explored the combined action of these four peptides across overlapping and complementary biological pathways
No comparable research exists yet for the injection method, meaning, direct comparison isnt possible at this stage